Erasca, Inc.
$13.18
+1.2%Erasca, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's lead candidates include ERAS-007, an oral inhibitor of ERK1/2 for the treatment of non-small cell lung cancer, colorectal cancer, and acute myeloid leukemia; and ERAS-601, an oral SHP2 inhibitor for patients with advanced or metastatic solid tumors. It is also developing ERAS-801, a central nervous system-penetrant EGFR inhibitor for the treatment of patients with recurrent glioblastoma multiforme. The company was incorporated in 2018 and is headquartered in San Diego, California.
At a Glance
Live SnapshotIntrinsic Alpha Methodology
Thesis Lenses
Signal
Medium confidenceValuation multiple is compressed (P/E -29.9).
Valuation inputs: P/E -29.9, earnings yield N/A, momentum +1.2%.
If multiples stay elevated while momentum fades, downside repricing risk rises.
Driver
High confidenceReturn profile is soft (ROE -38.3%, ROIC -35.3%).
Profitability stack: net margin 0.0%, ROE -38.3%, ROIC -35.3%.
Quality deterioration often appears in margins before it shows up in headline EPS.
Risk
High confidenceRisk profile is balanced but has notable pressure points to monitor.
Risk factors: liabilities/assets +17.9%, momentum +1.2%, net margin 0.0%.
Higher leverage with weak momentum and thin margins can amplify drawdown severity.
Erasca, Inc. Market vs Earnings Trajectory
Loading price and EPS data...
Erasca, Inc. Fair Value Envelope
No Revenue Data
ERAS has not reported any revenue values in the available annual periods.
Erasca, Inc. Profit Bridge
Profitability Analysis
No Gross Profit Margin Data
ERAS has not reported any gross profit margin values in the available annual periods.
No Operating Profit Margin Data
ERAS has not reported any operating profit margin values in the available annual periods.
No Net Profit Margin Data
ERAS has not reported any net profit margin values in the available annual periods.
Erasca, Inc. Cash Conversion Engine
Cash Flow Quality Analysis
FCF Conversion Rate
Moderate conversion rate. Some gap between earnings and cash flow may warrant investigation into working capital or non-cash items.
CapEx Intensity
Asset-light business model. Low capital requirements leave more cash available for shareholders and growth investments.
FCF Growth Trend
Strong FCF growth demonstrates improving cash generation and business momentum. Positive signal for sustainability.
Working Capital Impact
Minimal working capital impact on FCF. Changes in operating assets and liabilities well-managed.
Cash Flow Quality Insight
Working capital strain: Significant cash tied up in operations. Monitor receivables collection, inventory turns, and payment terms to optimize cash conversion cycle.
Erasca, Inc. Funding & Solvency Profile
Financial Health Analysis
Current Ratio
Excellent liquidity position. The company can easily cover its short-term obligations with substantial cushion.
Debt-to-Equity Ratio
Conservative capital structure. The company relies primarily on equity financing, indicating low financial risk.
Working Capital
Strong working capital position provides significant operational flexibility and financial cushion.
Asset Composition
Balanced asset mix between current and non-current assets, typical of many stable businesses.
Financial Health Insight
Strong financial foundation: Excellent liquidity combined with conservative leverage suggests the company is well-positioned to weather economic uncertainties and fund growth opportunities.
Erasca, Inc. Street Expectations Map
Wall Street analysts project that ERAS stock may rise significantly over the coming 12 months. The consensus 1-year price target stands at 17.80, with estimates ranging from a low of 10.00 to a high of 30.00.
The consensus 1-year price target stands at 17.80, with estimates ranging from a low of 10.00 to a high of 30.00.
Analyst Consensus Analysis
Upside Potential
Substantial upside potential. Analysts see significant value gap, suggesting the stock may be materially undervalued at current levels.
Analyst Agreement
High uncertainty. Very wide target spread indicates significant disagreement among analysts—major valuation uncertainty or transformation underway.
Risk-Reward Profile
Favorable risk-reward. Potential upside significantly exceeds downside risk, offering asymmetric return profile attractive for risk-tolerant investors.
Analyst Conviction
High uncertainty: Wide dispersion indicates analysts struggle to agree on valuation—proceed with caution and independent analysis.
Market Sentiment Insight
High risk, high reward: Substantial upside potential exists, but wide analyst disagreement signals execution risk or unclear catalysts. Thorough due diligence essential before committing capital.
Erasca, Inc. Insider Positioning
During the last 12 months, insiders have purchased $1.22M and sold $2.28M worth of ERAS shares, resulting in $1.07M of net selling activity.
3 Months
0
0.00
80.0K
1.31M
-1.3M
-$1.31M
3-6 Months
0
0.00
140.0K
971.57K
-972K
-$972K
6-9 Months
0
0.00
0
0.00
+0
+$0
9-12 Months
840.0K
1.22M
0
0.00
+1.2M
+$1.22M
Top Buyers
Start Valerie Denise Harding
Director
$174K
Multani Pratik S
Director
$174K
Bristol James Arthur
Director
$174K
Casdin Alexander W.
Director
$174K
Varney Michael David
Director
$174K
Top Sellers
Garner Ebun
Officer: Chief Legal Officer
$1.98M
Morris Shannon
Officer: Chief Medical Officer
$301K
Insider Activity Analysis
Net Insider Sentiment
Slightly bearish with $1.07M net selling. Selling modestly exceeds buying, which could be routine diversification rather than concern.
Buy/Sell Ratio
Moderately negative ratio. Selling is roughly double the buying, which may be routine or signal caution.
Recent Trend (3 Months)
Heavy recent selling activity. Recent insider sales notably exceed purchases—may warrant investigation into company developments.
Insider Participation
5 insider buyers vs. 2 sellers. Broad-based buying across management team suggests widespread confidence.
No Dividend Yield Data
ERAS has not reported any dividend yield values in the available annual periods.
eras Dividend History
Learning Layer
Related Guides
Build conviction on ERAS by pairing this stock hub with focused valuation guides.
Research Paths
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.